A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

Rajiv Agarwal, Chandan Saha, Meher Battiwala, Nina Vasavada, Timothy Curley, Shawn D. Chase, Nadine Sachs, Merfake H. Semret

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background. Diabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD). Animal experiments have found that peroxisome proliferator activated receptor-γ (PPAR-γ)-based therapy can have a glucose independent effect on renal protection. We hypothesized that PPAR-y-based antidiabetic therapy would result in greater reduction in proteinuria compared to sulfonylurea-based therapy. Methods. In 44 patients with overt diabetic nephropathy, an open-label, blinded end point trial was conducted in which subjects were randomized to either pioglitazone or glipizide to achieve similar glucose control. Proteinuria was assessed by two collections of 24-hour urine samples each month for 4 months. Results. The glipizide group had an adjusted mean increase in proteinuria of 6.1% (95% CI -11.7%, 23.8%), whereas the pi-oglitazone group had a reduction of 7.2% (95% CI -24.9%, 10.6%). The adjusted reduction with pioglitazone of 13.2% (95% CI -38.4%, 11.9%) was not statistically significant (P = 0.294). Baseline proteinuria, diastolic ambulatory blood pressure, and serum albumin concentration were independent predictors of reduction in proteinuria. The frequency and patterns of adverse events were similar in the two groups. Conclusion. In patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months. These data are useful to design larger studies with longer duration of follow-up to demonstrate renal protection of PPAR-γ agonists.

Original languageEnglish (US)
Pages (from-to)285-292
Number of pages8
JournalKidney International
Volume68
Issue number1
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

pioglitazone
Diabetic Nephropathies
Proteinuria
Randomized Controlled Trials
Kidney
Peroxisome Proliferator-Activated Receptors
Glipizide
Glucose
Hypoglycemic Agents
Serum Albumin
Chronic Kidney Failure
Therapeutics
Urine

Keywords

  • Ambulatory blood pressure monitoring
  • Diabetic nephropathy
  • Glomerular filtration rate
  • Pioglitazone
  • Proteinuria

ASJC Scopus subject areas

  • Nephrology

Cite this

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. / Agarwal, Rajiv; Saha, Chandan; Battiwala, Meher; Vasavada, Nina; Curley, Timothy; Chase, Shawn D.; Sachs, Nadine; Semret, Merfake H.

In: Kidney International, Vol. 68, No. 1, 07.2005, p. 285-292.

Research output: Contribution to journalArticle

Agarwal, Rajiv ; Saha, Chandan ; Battiwala, Meher ; Vasavada, Nina ; Curley, Timothy ; Chase, Shawn D. ; Sachs, Nadine ; Semret, Merfake H. / A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. In: Kidney International. 2005 ; Vol. 68, No. 1. pp. 285-292.
@article{7e42cc5e385340b9abe69127d4d3c9d4,
title = "A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy",
abstract = "Background. Diabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD). Animal experiments have found that peroxisome proliferator activated receptor-γ (PPAR-γ)-based therapy can have a glucose independent effect on renal protection. We hypothesized that PPAR-y-based antidiabetic therapy would result in greater reduction in proteinuria compared to sulfonylurea-based therapy. Methods. In 44 patients with overt diabetic nephropathy, an open-label, blinded end point trial was conducted in which subjects were randomized to either pioglitazone or glipizide to achieve similar glucose control. Proteinuria was assessed by two collections of 24-hour urine samples each month for 4 months. Results. The glipizide group had an adjusted mean increase in proteinuria of 6.1{\%} (95{\%} CI -11.7{\%}, 23.8{\%}), whereas the pi-oglitazone group had a reduction of 7.2{\%} (95{\%} CI -24.9{\%}, 10.6{\%}). The adjusted reduction with pioglitazone of 13.2{\%} (95{\%} CI -38.4{\%}, 11.9{\%}) was not statistically significant (P = 0.294). Baseline proteinuria, diastolic ambulatory blood pressure, and serum albumin concentration were independent predictors of reduction in proteinuria. The frequency and patterns of adverse events were similar in the two groups. Conclusion. In patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months. These data are useful to design larger studies with longer duration of follow-up to demonstrate renal protection of PPAR-γ agonists.",
keywords = "Ambulatory blood pressure monitoring, Diabetic nephropathy, Glomerular filtration rate, Pioglitazone, Proteinuria",
author = "Rajiv Agarwal and Chandan Saha and Meher Battiwala and Nina Vasavada and Timothy Curley and Chase, {Shawn D.} and Nadine Sachs and Semret, {Merfake H.}",
year = "2005",
month = "7",
doi = "10.1111/j.1523-1755.2005.00416.x",
language = "English (US)",
volume = "68",
pages = "285--292",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

AU - Agarwal, Rajiv

AU - Saha, Chandan

AU - Battiwala, Meher

AU - Vasavada, Nina

AU - Curley, Timothy

AU - Chase, Shawn D.

AU - Sachs, Nadine

AU - Semret, Merfake H.

PY - 2005/7

Y1 - 2005/7

N2 - Background. Diabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD). Animal experiments have found that peroxisome proliferator activated receptor-γ (PPAR-γ)-based therapy can have a glucose independent effect on renal protection. We hypothesized that PPAR-y-based antidiabetic therapy would result in greater reduction in proteinuria compared to sulfonylurea-based therapy. Methods. In 44 patients with overt diabetic nephropathy, an open-label, blinded end point trial was conducted in which subjects were randomized to either pioglitazone or glipizide to achieve similar glucose control. Proteinuria was assessed by two collections of 24-hour urine samples each month for 4 months. Results. The glipizide group had an adjusted mean increase in proteinuria of 6.1% (95% CI -11.7%, 23.8%), whereas the pi-oglitazone group had a reduction of 7.2% (95% CI -24.9%, 10.6%). The adjusted reduction with pioglitazone of 13.2% (95% CI -38.4%, 11.9%) was not statistically significant (P = 0.294). Baseline proteinuria, diastolic ambulatory blood pressure, and serum albumin concentration were independent predictors of reduction in proteinuria. The frequency and patterns of adverse events were similar in the two groups. Conclusion. In patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months. These data are useful to design larger studies with longer duration of follow-up to demonstrate renal protection of PPAR-γ agonists.

AB - Background. Diabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD). Animal experiments have found that peroxisome proliferator activated receptor-γ (PPAR-γ)-based therapy can have a glucose independent effect on renal protection. We hypothesized that PPAR-y-based antidiabetic therapy would result in greater reduction in proteinuria compared to sulfonylurea-based therapy. Methods. In 44 patients with overt diabetic nephropathy, an open-label, blinded end point trial was conducted in which subjects were randomized to either pioglitazone or glipizide to achieve similar glucose control. Proteinuria was assessed by two collections of 24-hour urine samples each month for 4 months. Results. The glipizide group had an adjusted mean increase in proteinuria of 6.1% (95% CI -11.7%, 23.8%), whereas the pi-oglitazone group had a reduction of 7.2% (95% CI -24.9%, 10.6%). The adjusted reduction with pioglitazone of 13.2% (95% CI -38.4%, 11.9%) was not statistically significant (P = 0.294). Baseline proteinuria, diastolic ambulatory blood pressure, and serum albumin concentration were independent predictors of reduction in proteinuria. The frequency and patterns of adverse events were similar in the two groups. Conclusion. In patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months. These data are useful to design larger studies with longer duration of follow-up to demonstrate renal protection of PPAR-γ agonists.

KW - Ambulatory blood pressure monitoring

KW - Diabetic nephropathy

KW - Glomerular filtration rate

KW - Pioglitazone

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=24944536256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944536256&partnerID=8YFLogxK

U2 - 10.1111/j.1523-1755.2005.00416.x

DO - 10.1111/j.1523-1755.2005.00416.x

M3 - Article

C2 - 15954919

AN - SCOPUS:24944536256

VL - 68

SP - 285

EP - 292

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -